Wedbush Issues Positive Outlook for KNSA Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities researchers at Wedbush raised their Q1 2025 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a research report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of $0.09. Wedbush currently has a “Outperform” rating and a $34.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS and FY2025 earnings at $0.56 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. During the same period last year, the business posted ($0.20) earnings per share. The company’s revenue for the quarter was up 67.4% compared to the same quarter last year.

Several other equities research analysts have also recently weighed in on KNSA. JPMorgan Chase & Co. upped their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Evercore ISI raised their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $18.54 on Thursday. Kiniksa Pharmaceuticals has a 1-year low of $16.56 and a 1-year high of $28.15. The firm has a market capitalization of $1.34 billion, a P/E ratio of -132.42 and a beta of 0.29. The company’s 50-day moving average is $20.67 and its 200 day moving average is $23.21.

Insider Activity

In related news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,092 shares of company stock worth $471,609 in the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in Kiniksa Pharmaceuticals by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company’s stock worth $2,150,000 after purchasing an additional 2,563 shares during the period. Arizona State Retirement System acquired a new position in Kiniksa Pharmaceuticals in the second quarter worth approximately $209,000. American Century Companies Inc. lifted its stake in shares of Kiniksa Pharmaceuticals by 33.4% in the 2nd quarter. American Century Companies Inc. now owns 29,226 shares of the company’s stock valued at $546,000 after purchasing an additional 7,314 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Kiniksa Pharmaceuticals in the second quarter valued at approximately $314,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.